Treatment of Alcoholic Liver Disease

Introduction to Alcoholic Liver Disease Treatment

The American Association for the Study of Liver Diseases recommends that alcohol abstinence is the single most critical intervention for all stages of alcoholic liver disease, and must be combined with stage-specific medical management including nutritional support, pharmacotherapy for alcohol use disorder tailored to liver function, and corticosteroids for severe alcoholic hepatitis 1, 2, 3

The American Association for the Study of Liver Diseases suggests that abstinence or controlled drinking is the primary treatment for alcoholic fatty liver, as this stage is reversible with cessation of alcohol intake 2, 3
The American Association for the Study of Liver Diseases recommends thiamine supplementation 100-300 mg/day for 2-3 months to prevent Wernicke encephalopathy in patients with alcoholic liver disease 4

The American Association for the Study of Liver Diseases recommends using mDF score and MELD score to determine prognosis and guide treatment decisions for patients with alcoholic hepatitis 2, 3
The American Association for the Study of Liver Diseases suggests that corticosteroids are first-line therapy for severe alcoholic hepatitis (mDF ≥32) 2, 3
The American Association for the Study of Liver Diseases recommends monitoring treatment response using the Lille model after 1 week of corticosteroid therapy for patients with alcoholic hepatitis 2, 3

The American Association for the Study of Liver Diseases states that alcohol withdrawal syndrome occurs 6-24 hours after cessation, with symptoms peaking at 3-5 days 2, 3, 4
The American Association for the Study of Liver Diseases recommends using CIWA protocol for severity assessment and treatment planning, but recognizes it can be falsely elevated in sepsis, hepatic encephalopathy, or anxiety disorders 2, 3, 4
The American Association for the Study of Liver Diseases suggests that long-acting benzodiazepines (chlordiazepoxide 25-100 mg every 4-6 hours or diazepam) are first-line for withdrawal prevention and seizure prophylaxis 4, 5

The American Association for the Study of Liver Diseases recommends screening for liver disease before selecting relapse prevention medication, as naltrexone is absolutely contraindicated in alcoholic liver disease due to hepatotoxicity risk 1, 5, 6, 7
The American Association for the Study of Liver Diseases suggests that naltrexone 50 mg daily (oral) or 380 mg monthly (intramuscular) is first-line pharmacotherapy for patients without liver disease 1, 5, 7
The American Association for the Study of Liver Diseases recommends acamprosate 666 mg three times daily (1998 mg total daily) as the preferred option for patients with alcoholic liver disease, because it has no hepatic metabolism and no reported hepatotoxicity 1, 5, 6, 7
The American Association for the Study of Liver Diseases suggests that baclofen 30-60 mg daily is the only medication with RCT evidence specifically in alcoholic liver disease patients and is recommended as first-line or second-line option 1, 5, 6, 7

The American Association for the Study of Liver Diseases recommends integrating alcohol use disorder treatment with medical care as the best approach for advanced ALD, and pharmacotherapy alone is insufficient 1, 5, 7
The American Association for the Study of Liver Diseases suggests that cognitive behavioral therapy (CBT) is first-line and should be combined with pharmacotherapy, focusing on identifying triggers, developing coping strategies, and restructuring thought patterns 1, 5, 7
The American Association for the Study of Liver Diseases recommends motivational interviewing as particularly effective for patients ambivalent about cessation, using techniques to help patients change behaviors 1, 5, 6, 7

The American Association for the Study of Liver Diseases recommends supplementing thiamine, folate, and other B vitamins to correct deficiencies in patients with alcoholic liver disease 4

The American Association for the Study of Liver Diseases recommends assessing for active alcohol withdrawal and initiating benzodiazepines and thiamine immediately if present 4, 5
The American Association for the Study of Liver Diseases suggests determining the stage of liver disease using clinical assessment, labs, and imaging 2, 3
The American Association for the Study of Liver Diseases recommends calculating mDF and MELD scores for alcoholic hepatitis patients to guide corticosteroid therapy 2, 3
The American Association for the Study of Liver Diseases suggests screening liver function before selecting relapse prevention medication 1, 5, 6, 7

The American Association for the Study of Liver Diseases warns to never use naltrexone in patients with active liver disease or elevated transaminases due to hepatotoxicity risk 1, 5, 6, 7
The American Association for the Study of Liver Diseases recommends to never rely solely on pharmacotherapy without behavioral interventions, as this significantly reduces treatment effectiveness 5, 7
The American Association for the Study of Liver Diseases suggests to never use disulfiram in ALD patients due to hepatotoxicity 1
The American Association for the Study of Liver Diseases warns to never discontinue treatment prematurely, with optimal duration being 3-6 months minimum 5, 7